Development of the General Scale Observance for Chronic Diseases

Completed

• Conditions: Chronic Diseases

• Registration Number: NCT02885129
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

The main objective is to assess the measurement characteristics (validity, reproducibility) and the invariance of EGOMAC scale in a population of consultants in diabetology, cardiology and rheumatology hospital and liberal and hospital oncology and Infectious disease, by following the evolution of patient compliance at D0 and D15.

The second objective is to assess the sensitivity to change of scale EGOMAC following developments compliance 3 months.

Detailed Description

During a routine appointment (D0), the patient filled a newsletter and a questionnaire to complete.

The doctor collects medical informations for the case report form.

At the end of the first consultation (D0), an additional EGOMAC scale and a stamped envelope is delivered to the patient by asking him to fill that scale to 15 days and return it by Post Office (reproducibility study).

Finally, a new scale will be addressed to the patient at the end of 3 months, which will return by Post Office too (stability study).

Study Timeline

• Study Start: 2014-06
• Study First Submitted: 2016-08-23
• Study First Submitted QC: 2016-08-26
• Study First Posted: 2016-08-31
• Primary Completion: 2017-04
• Study Completion: 2017-04
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-13
• Last Update Posted: 2017-08-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 397

Inclusion Criteria

• patient age of 18 years
• from routine patient counseling
• with at least one of these diseases : heart failure, hypertension, coronary disease, type 2 diabetes, osteoarthritis of the knee or hip, osteoporosis, inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy), cancer ( with only non-hormonal oral anti cancer treatments) and HIV.
• patient can read the French language in order to complete the self -administered questionnaire
• patient agreeing to participate in the study

Exclusion Criteria

• patient treated for more than 3 conditions mentioned in the inclusion criteria (
• patient receiving no drug prescription or recommendation of lifestyle or diet (for example consultationpurely diagnostic ).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
EGOMAC questionnaire	baseline
Change in EGOMAC questionnaire	15 days

Trial Locations

Locations (1)

Central hospital; 🇫🇷 Nancy, France